# QuVa Pharma, Inc., Sugar Land, TX – FDA Inspections

Source: https://www.keypedia.com/companies/quva-pharma-inc/1c3d31f9-2be4-48a3-84d3-e65f3344acd9

> Inspection records and compliance data for QuVa Pharma, Inc. in Sugar Land, Texas. 6 FDA inspections on record (1 OAI), 4 Form 483s, last inspected May 04, 2026.

---

## Details

- Name: QuVa Pharma, Inc.
- FEI Number: 3012053582
- Address Line 1: 1075 W Park One Dr Ste 100
- City: Sugar Land
- State: Texas
- Zip Code: 77478
- Country Name: United States
- Address: 1075 W Park One Dr Ste 100, Sugar Land, Texas 77478, United States
- Country: United States

## Related Documents

- [483 - QuVa Pharma, Inc. - 2026-05-04](https://www.keypedia.com/records/483/quva-pharma-inc/ab766466-4b36-432c-980d-621f2c79fd14) — source: FDA, date: May 4, 2026
- [FDA Inspection 1282296 - QuVa Pharma, Inc. - 2026-05-04](https://www.keypedia.com/records/fda_inspections/quva-pharma-inc/ed8a4068-cb2f-474c-96db-d15e17113651) — source: FDA, date: May 4, 2026
- [483 - QuVa Pharma, Inc. - 2024-10-28](https://www.keypedia.com/records/483/quva-pharma-inc/86384d71-640f-40d7-82b8-4214030ed2f4) — source: FDA, date: October 28, 2024
- [FDA Inspection 1238474 - QuVa Pharma, Inc. - 2024-10-28](https://www.keypedia.com/records/fda_inspections/quva-pharma-inc/cc614ef7-bea2-4730-8607-e4f953a946fb) — classification: Voluntary Action Indicated (VAI), source: FDA, date: October 28, 2024
- [UNTITLED_LETTER - QuVa Pharma, Inc. - 2024-09-24](https://www.keypedia.com/records/untitled_letter/quva-pharma-inc/9807dbff-8897-48ee-bc96-bc877d478daf) — source: FDA, date: September 24, 2024
- [FDA Inspection 1177937 - QuVa Pharma, Inc. - 2022-08-18](https://www.keypedia.com/records/fda_inspections/quva-pharma-inc/97908c4c-919d-41af-bcef-d54cbf973a9b) — classification: Voluntary Action Indicated (VAI), source: FDA, date: August 18, 2022
- [FDA Inspection 1087147 - QuVa Pharma, Inc. - 2019-04-23](https://www.keypedia.com/records/fda_inspections/quva-pharma-inc/fa2666c5-49b3-4d5a-ac17-7936e2f05fbc) — classification: Official Action Indicated (OAI), source: FDA, date: April 23, 2019
- [FDA Inspection 1012820 - QuVa Pharma, Inc. - 2017-06-02](https://www.keypedia.com/records/fda_inspections/quva-pharma-inc/e07d3c56-3f07-4db6-819c-bc6b04f5d745) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 2, 2017
- FDA Inspection 957761 - QuVa Pharma, Inc. - 2016-02-08 — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 8, 2016

## Related Companies

- [Hans C. Lee, M.D.](https://www.keypedia.com/companies/hans-c-lee-md/7280a127-79bb-4842-acd5-2e1ac3f7ef7a)
- [Imran S. Khawaja, M.D.](https://www.keypedia.com/companies/imran-s-khawaja-md/dc9b2ff3-c377-49a3-93fb-5d14cf0e9161)
- [Shahrukh A. Kureishy, MD](https://www.keypedia.com/companies/shahrukh-a-kureishy-md/5a1e7d4e-2c47-4051-9af8-bdba6c8a391b)
- [Shannon R. Schrader, M.D.](https://www.keypedia.com/companies/shannon-r-schrader-md/8bdbeb81-6983-4a71-8165-9660ecc7ef00)
- [Stephen K. Tyring, MD, PhD](https://www.keypedia.com/companies/stephen-k-tyring-md-phd/6c5d7be1-a87b-4923-8e28-a0ff88addbb8)
- [Roy F. Chemaly](https://www.keypedia.com/companies/roy-f-chemaly/64593ffc-4ed7-4c6b-8244-4f09fdb33763)
- [David R. Hensley, MD](https://www.keypedia.com/companies/david-r-hensley-md/7993a043-4f38-4152-9d15-d11e31ec31ad)
- [Adam I. Frome, MD](https://www.keypedia.com/companies/adam-i-frome-md/e167580a-0d54-4083-adef-f11ed510ddff)
- [Hina Budhwani](https://www.keypedia.com/companies/hina-budhwani/b46402a3-5aab-4e07-a73c-4bfe6c1858c3)
- [Marlinz Pharma, LLC](https://www.keypedia.com/companies/marlinz-pharma-llc/66897e87-8f53-4e28-86b4-e6db39fd3dce)

## Related Officers

- [Microbiologist](https://www.keypedia.com/people/camerson-e-moore/50733244-0d55-4b0b-a758-f192b7c66457)
- [Director](https://www.keypedia.com/people/frances-g-bormel/75a42bda-8a74-4dd2-a081-c7f1bf9cf417)